Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study
Sponsor: Catalyst Pharmaceuticals, Inc.
Terminated
To conserve remaining capital, Sponsor decided to terminate the study early.
Other terminated trials from Catalyst Pharmaceuticals, Inc.
- AChR Myasthenia Gravis · Phase PHASE3 · Aug 2022
- Spinal Muscular Atrophy Type 3 · Phase PHASE2 · Sep 2021
More terminations from Catalyst Pharmaceuticals, Inc.
Other Methamphetamine Dependence trials with similar outcome
A PHASE2 clinical study on Methamphetamine Dependence, this trial is terminated or withdrawn. The trial is conducted by Catalyst Pharmaceuticals, Inc. and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Catalyst Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .